Figure 1.

Comparisons of survival according to treatment strategy or metabolic tumor burden using ¹⁸F‐fluoro‐deoxyglucose positron emission tomography (¹⁸F‐FDG‐PET) in patients with early stage Hodgkin's lymphoma (HL). In a median follow‐up time of 45.8 months, progression‐free survival (PFS) and overall survival (OS) in the combined modality treatment (CMT) group were not significantly different with the doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) only group (PFS, 91.8% in the CMT group vs 80.3% in the ABVD only group, P = 0.056 [a]; OS, 91.8% in the CMT group vs 84.8% in the ABVD only group, P = 0.151, [b]). The PFS and OS were higher in the low metabolic tumor volume (MTV) group compared with that in the high MTV group (PFS, 96.3% in the low MTV group vs 66.7% in the high MTV group, P < 0.001 [c]; OS, 97.6% in the low MTV group vs 71.1% in the high MTV group, P = 0.001 [d]).